Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/29/2009 First Published: 6/23/2003


1.		Phase III Randomized Study of Doxorubicin, Cisplatin, Paclitaxel, and Filgrastim (G-CSF) Versus Carboplatin and Paclitaxel in Patients With Stage III or IV or Recurrent Endometrial Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				GOG-0209 NCT00063999

First Published: 12/10/2008


2.		Phase III Randomized Study of Pelvic Radiotherapy Versus Vaginal Cuff Brachytherapy, Paclitaxel, and Carboplatin in Patients With High-Risk Stage I or II Endometrial Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 and over				NCI				GOG-0249 GOG-0249, NCT00807768

Last Modified: 5/28/2008 First Published: 11/18/2005


3.		Phase II Study of Induction Chemotherapy Comprising Carboplatin and Docetaxel Followed by Radiotherapy and Consolidation Chemotherapy Comprising Carboplatin and Docetaxel in Patients With Stage III or IV or Recurrent Endometrial Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				UMN-2004LS021 UMN-WCC-38, NCT00258362

Last Modified: 1/8/2008 First Published: 5/21/2007


4.		Phase II Study of Sunitinib Malate in Patients With Recurrent or Metastatic Endometrial Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				PMH-PHL-062 7713, PHL-062, NCT00478426

Last Modified: 5/22/2008 First Published: 5/4/2007


5.		Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				Any age				NCI				CINJ-3330 NCT00161187

Last Modified: 1/24/2009 First Published: 6/21/2007


6.		Phase II Randomized Study of Pelvic Radiotherapy With Versus Without Cisplatin in Patients With Recurrent Endometrial Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Not specified				NCI				GOG-0238 GOG-0238, NCT00492778

Last Modified: 1/23/2009 First Published: 7/13/2007


7.		Phase II Randomized Study of Megestrol Acetate in Patients With Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				GOG-0224 GOG-0224, NCT00503581

Last Modified: 5/15/2008 First Published: 3/12/2008


8.		Phase II Study of AZD0530 in Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				PMH-PHL-054 PHL-054, 7557, NCT00659360

Last Modified: 1/29/2009 First Published: 8/5/2008


9.		Phase II Randomized Study of Temsirolimus With or Without Hormonal Therapy Comprising Megestrol Acetate and Tamoxifen Citrate in Patients With Advanced, Persistent, or Recurrent Endometrial Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Not specified				NCI				GOG-0248 GOG-0248, NCT00729586

First Published: 1/7/2009


10.		Phase II Study of Gemcitabine Hydrochloride in Patients With Recurrent or Persistent Endometrial Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Approved-not yet active				18 and over				NCI				GOG-0129Q GOG-0129Q, NCT00820898

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute